Eribulin Mesylate, a synthetic analogue of halichondrin B derived from marine sponges, has emerged as a critical oncology therapeutic primarily indicated for metastatic breast cancer and liposarcoma. As a microtubule dynamics inhibitor, it disrupts cell division and has become an essential component of cancer treatment protocols worldwide. With the global pharmaceutical-grade Eribulin Mesylate market valued at approximately US428–440millionin2024andprojectedtoreachUS428–440millionin2024andprojectedtoreachUS 582–595 million by 2031, understanding the global buyers landscape is essential for suppliers, distributors, and procurement professionals. This comprehensive guide provides an in-depth analysis of the Eribulin global buyers list, covering key importers, distributors, procurement channels, and market dynamics that shape the international trade of this vital oncology drug. Global Market Overview The…